Maritech 926 Seaweed Derivative Shown to Inhibit H1N1 Virus

Introduction

In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus.

Main Digest

The extract - known as Maritech® 926 - is a fucoidan compound derived from the Undaria pinnatifida species of seaweed. In vitro tests performed under contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in the US, have shown that Maritech® 926 can inhibit the H1N1 influenza virus at extremely low concentrations.

Developed by biotechnology company Marinova Pty Ltd, Maritech® 926 is a natural polysaccharide which has immediate market potential in nutritional supplements, hand washes and nasal delivery products which target the spread and prevention of viral conditions.

Scope also exists for the compound to be included in pharmaceutical and medical device applications.

As a result of these findings, Marinova has filed for patent protection over the application of Maritech® 926 and other fucoidan extracts in a range of anti-viral applications.

In announcing the findings and patent filing, Marinova's Senior Scientist, Dr Helen Fitton, said:

"Fucoidan extracts such as Maritech® 926 are known to have significant inhibitory effects on a range of coated viruses. We are particularly excited by the fact that these seaweed extracts have now been shown to have an inhibitory effect on H1N1 at extremely low concentrations. With H1N1 already becoming resistant to some other antiviral agents, we believe that Maritech® 926 offers a potent, natural alternative which supports the immune system against viral attacks".

Marinova Pty Ltd is an Australian biotechnology company, with extensive research and manufacturing facilities in Hobart, Tasmania. The company is dedicated to creating innovative and chemically consistent extracts from marine plants for use in medical, nutritional and skin care applications. Using its proprietary solvent-free Maritech® process, Marinova has the unique ability to supply high-purity fucoidan ingredients which not only meet HACCP, ISO9001, GMP and Organic quality requirements, but also comply with FDA and European pharmaceutical standards.

Attribution/Source(s):

This quality-reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by Marinova Pty Ltd, and published on 2010/05/05 (Edit Update: 2023/06/12), the content may have been edited for style, clarity, or brevity. For further details or clarifications, Marinova Pty Ltd can be contacted at marinova.com.au. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Related Publications▶ Share This Page

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Marinova Pty Ltd. (2010, May 5 - Last revised: 2023, June 12). Maritech 926 Seaweed Derivative Shown to Inhibit H1N1 Virus. Disabled World. Retrieved September 12, 2024 from www.disabled-world.com/health/influenza/swine-flu/seaweed-h1n1.php

Permalink: <a href="https://www.disabled-world.com/health/influenza/swine-flu/seaweed-h1n1.php">Maritech 926 Seaweed Derivative Shown to Inhibit H1N1 Virus</a>: Australian scientists in Swine Flu breakthrough as seaweed derivative shown to inhibit H1N1 virus.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.